stockrow
Friday 6 November 2026
Export CATX’s income statement to Excel — free account
Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.
- Revenue
- −72.1%
- EPS
- +24.1%
- Free cash flow
- −66.1%
- Total debt
- −3.57%
Quarter to June 2026, against a year earlier
0.84
0.05
+6.33%
Follow CATX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | — | — | — | 1 | 4 | 3 | 6 | 4 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
229.62 | 141.35 | 74.84 | — | 4.07 | 82.43 | 38.83 | 37.58 | 40.70 | 72.22 |
Altman Z-Score |
(0.59) | 1.37 | (0.69) | — | 7.08 | 15.80 | (6.24) | (3.36) | (10.36) | 3.68 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.38) | 6.14 | (4.33) | — | 20.50 | 25.06 | (30.66) | (24.04) | (35.41) | (11.16) |
P/Operating CF |
(8.23) | (7.72) | (11.91) | — | (15.18) | (741.19) | (443.23) | (279.06) | (166.47) | (283.47) |
Beneish M-Score |
0.59 | (4.35) | — | — | (1.76) | (2.56) | (1.41) | (2.65) | (3.25) | (3.45) |
P/B ratio |
0.98 | 0.71 | 1.43 | — | 0.72 | 12.29 | 65.68 | 35.79 | 47.92 | 32.43 |
Price to Tangible BV |
1.22 | 0.85 | 96.08 | — | 0.72 | 12.32 | 67.30 | 35.79 | 47.92 | 32.43 |
EV/Sales |
67.67 | (13.60) | 69.57 | — | (1.09) | 76.13 | 38.66 | 36.85 | 40.12 | 70.98 |
EV/EBITDA |
0.00 | 0.30 | 0.00 | — | 3.56 | 20,140.72 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.73) | 1.08 | (2.70) | — | 1.52 | (194.50) | (67.16) | (34.67) | (26.71) | (38.73) |
EV/FCF |
(0.63) | 0.27 | (2.63) | — | 1.47 | (170.53) | (61.87) | (32.14) | (25.32) | (35.54) |
Quick Ratio |
5.05 | 12.45 | 0.66 | 16.43 | 25.37 | 36.56 | 2.82 | 5.78 | 2.52 | 6.02 |
Current Ratio |
5.17 | 12.68 | 1.07 | 17.07 | 26.18 | 37.37 | 3.50 | 6.53 | 2.97 | 9.30 |
Net Debt/EBITDA |
1.27 | 3.46 | 0.19 | 0.00 | 9.06 | 19.60 | 0.50 | 1.05 | 0.52 | 0.96 |
Debt/Assets |
0.59% | 0.48% | 1.71% | 0.00% | 0.40% | 0.74% | 8.84% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.01 | 0.13 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.02 | 0.00 | 0.16 | 0.25 | 1.07 | 0.87 | 0.60 | 0.31 |
Operating CF/Net income |
0.80 | 0.23 | 0.79 | — | 1.06 | 0.84 | 1.05 | 0.98 | 0.85 | 0.93 |
Capex/Depreciation |
(24.15) | (2.10) | (1.09) | — | (0.95) | (1.75) | (1.28) | (2.46) | (3.09) | (5.60) |
Interest Coverage |
(302.03) | (1,893.46) | (499.28) | — | (53.94) | (58.41) | (115.87) | (48.65) | (232.03) | (53.45) |
| (41.44%) | (43.34%) | (71.65%) | 0.00% | (11.30%) | (9.27%) | (51.59%) | (81.12%) | (85.86%) | (45.72%) | |
| (33.92%) | (36.12%) | (59.63%) | 0.00% | (10.78%) | (8.57%) | (38.15%) | (61.09%) | (68.05%) | (40.65%) | |
ROIC |
(111.14%) | (86.89%) | (37.84%) | 0.00% | (71.09%) | (52.50%) | (52.99%) | (139.50%) | (262.03%) | (84.41%) |
Return on Tangible Assets |
(52.53%) | (29.34%) | (689.11%) | 0.00% | (12.32%) | (5.03%) | (61.00%) | (66.06%) | (136.35%) | (60.29%) |
Average Days of Receivables |
2.48 | 29.12 | 296.53 | 0.00 | 54.37 | 73.09 | 77.07 | 57.59 | 73.46 | 55.66 |
Research and Development Expense of Revenue |
9,526.58% | 2,863.69% | 1,486.12% | — | 7.87% | 14.19% | 11.63% | 20.15% | 29.48% | 20.27% |
Selling, General and Administrative Expense of Revenue |
3,420.02% | 1,830.33% | 1,468.90% | — | 51.59% | 70.93% | 77.96% | 93.67% | 115.23% | 130.85% |
Intangible Assets out of Total Assets |
0.15 | 0.15 | 0.76 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.02 |
Share Based Compensation of Revenue |
1,014.25% | 370.50% | 260.67% | — | 10.07% | 3.84% | 5.11% | 5.74% | 10.25% | 7.81% |
Graham Net Nets |
0.44 | 0.88 | (0.05) | — | 1.28 | 0.08 | 0.01 | 0.02 | 0.01 | 0.03 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(50.80%) | (37.08%) | (43.78%) | — | (16.32%) | (3.39%) | (5.76%) | (15.12%) | (19.22%) | (13.28%) |
Free Cash Flow Yield |
(46.92%) | (35.22%) | (35.39%) | — | (18.18%) | (0.54%) | (1.61%) | (3.05%) | (3.89%) | (2.77%) |
Revenue per Share |
0.01 | 0.02 | 0.05 | — | 0.76 | 0.97 | 1.43 | 1.09 | 1.07 | 0.87 |
Operating CF per Share |
(1.12) | (0.28) | (1.38) | — | (0.54) | (0.27) | (0.54) | (0.75) | (1.04) | (1.04) |
Capex per Share |
(0.17) | (0.84) | (0.04) | — | (0.02) | (0.04) | (0.04) | (0.06) | (0.06) | (0.10) |
Free Cash Flow per Share |
(1.29) | (1.12) | (1.42) | — | (0.56) | (0.31) | (0.58) | (0.81) | (1.10) | (1.14) |
Cash per Share |
1.96 | 3.52 | 0.35 | 0.00 | 3.94 | 6.15 | 0.35 | 0.79 | 0.62 | 1.08 |
Shareholders Equity per Share |
2.80 | 4.51 | 2.81 | 0.00 | 4.32 | 6.49 | 0.85 | 1.15 | 0.91 | 1.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.80 | 4.51 | 2.81 | 0.00 | 4.32 | 6.49 | 0.85 | 1.15 | 0.91 | 1.93 |
Free Cash Flow |
(95.23) | (72.37) | (37.98) | — | (7.98) | (3.22) | (3.91) | (5.46) | (6.05) | (6.25) |
Working Capital |
119.71 | 212.93 | 1.17 | 50.10 | 57.06 | 65.50 | 3.93 | 6.19 | 3.61 | 9.19 |
Capital Expenditures |
(12.75) | (54.08) | (1.07) | — | (0.27) | (0.38) | (0.27) | (0.41) | (0.34) | (0.54) |
Net Current Asset Value |
88.45 | 180.73 | (5.87) | 49.77 | 56.17 | 64.29 | 2.53 | 5.57 | 3.02 | 8.62 |
EV/EBIT |
0.00 | 0.22 | 0.00 | — | 1.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
14.42 | 37.19 | 0.75 | — | 0.02 | 0.04 | 0.03 | 0.06 | 0.06 | 0.11 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.01 | 0.45 | 0.18 | 0.00 | 0.14 | 0.11 | 0.12 | 0.10 | 0.08 | 0.09 |
Cash ROIC |
(26.95%) | (13.94%) | (44.12%) | 0.00% | (6.79%) | (2.44%) | (44.06%) | (41.97%) | (71.54%) | (37.83%) |
Accounts Receivable Turnover |
14.49 | 2.27 | 0.33 | 0.00 | 5.96 | 4.96 | 6.05 | 6.24 | 6.18 | 7.15 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.13 | 6.82 | 4.11 | 4.04 | 6.32 |
Inventory Turnover |
— | — | — | — | 0.00 | 6.07 | 7.75 | 8.33 | 9.99 | 11.94 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.02 | 52.39 | 58.42 | 124.41 | 58.62 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 72.53 | 51.67 | 45.34 | 44.18 | 30.05 |
Average Receivables |
0.06 | 0.64 | 4.32 | 4.54 | 1.81 | 2.03 | 1.60 | 1.17 | 0.96 | 0.67 |
Average Payables |
15.43 | 8.63 | 4.23 | 1.25 | 0.85 | 0.69 | 0.67 | 1.04 | 1.01 | 0.62 |
Average Inventory |
— | — | — | — | 1.19 | 0.81 | 0.59 | 0.51 | 0.41 | 0.33 |
Average Assets |
304.04 | 219.50 | 77.99 | 61.27 | 67.43 | 39.56 | 9.06 | 8.44 | 9.86 | 15.19 |
Average Common Equity |
248.85 | 182.92 | 64.91 | 57.96 | 64.34 | 36.56 | 6.70 | 6.36 | 7.82 | 13.50 |
Columns are period end dates · fundamentals updated 26 Oct 2026